


# **Data Sheet**

Product Name:SerdemetanCat. No.:CS-0166CAS No.:881202-45-5Molecular Formula: $C_{21}H_{20}N_4$ Molecular Weight:328.41

**Target:** Apoptosis; E1/E2/E3 Enzyme; MDM-2/p53 **Pathway:** Apoptosis; Metabolic Enzyme/Protease

**Solubility:** DMSO : 50 mg/mL (ultrasonic)



## **BIOLOGICAL ACTIVITY:**

Serdemetan (JNJ-26854165) is a potent **anticancer** agent with radiosensitizing activity. Serdemetan exhibits antiproliferative activity in various **p53** wild-type tumor cells. Serdemetan also antagonizes the **Mdm2-HIF1** $\alpha$  axis leading to decreased levels of glycolytic enzymes<sup>[1][2][3]</sup>. *In Vitro:*Serdemetan (0.5-50  $\mu$ M; 48-72 h) inhibits cell proliferation of H460, A549, p53-WT HCT116, p53-null HCT116 and HMEC-1 cells in a dose-dependent manner<sup>[1]</sup>.

Serdemetan (0.25-5 μM; 48 h) triggers cell arrests in G2/M phase of A549 cells and H460 cells<sup>[1]</sup>.

Serdemetan (0.5-10 µM; 48 h) increases expression of p53 and p21 in H460, A549 and p53-WT HCT116 cells[1].

Serdemetan (0.25-10 µM; 12-14 d) affects clonogenic survival in H460, A549 p53-WT HCT116 and p53-null HCT116 cells[1].

Serdemetan (0.25-5 µM; 12-14 d) increases radiation-induced clonogenic inhibition<sup>[1]</sup>.

Serdemetan (5-20  $\mu$ M; 4-24 h) inhibits neovessels formation and delays scratch wound repair of HMEC-1 cells<sup>[1]</sup>.

In Vivo: Serdemetan (50 mg/kg) enhances radiation-induced growth delays in H460 and A549 xenograft tumors<sup>[1]</sup>.

#### References:

- [1]. Chargari C, et, al. Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett. 2011 Dec 22;312(2):209-18.
- [2]. Lehman JA, et, al. Serdemetan antagonizes the Mdm2-HIF1 $\alpha$  axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8(9):e74741.
- [3]. Jones RJ, et, al. The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1. J Pharmacol Exp Ther. 2013 Sep;346(3):381-92.

#### **CAIndexNames:**

1,4-Benzenediamine, N1-[2-(1H-indol-3-yl)ethyl]-N4-4-pyridinyl-

## SMILES:

C1(NCCC2=CNC3=C2C=CC=C3)=CC=C(C=C1)NC4=CC=NC=C4

Page 1 of 2 www.ChemScene.com

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.ChemScene.com